AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1550076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic PAC chemotherapy
Number of subjects: 99
Study 1550076 — intervention group
Group type: COMPARATOR
Intervention: Brief PAC chemotherapy
Number of subjects: 99
Study 1550076 — intervention group
Group type: COMPARATOR
Intervention: FAM chemotherapy
Number of subjects: 99
Study 1550076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic PAC chemotherapy (Stage III or IV)
Number of subjects: 99
Study 1550076 — intervention group
Group type: COMPARATOR
Intervention: Brief PAC chemotherapy (Stage III or IV)
Number of subjects: 99
Study 1550076 — intervention group
Group type: COMPARATOR
Intervention: FAM chemotherapy (Stage III or IV)
Number of subjects: 99
Study 3901359 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 150
Study 3901359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 150
Study 3901359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Male students
Number of subjects: 2827
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Students whose mothers smoked
Number of subjects: 2827
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Students whose mothers had a higher educational level
Number of subjects: 2827
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2827
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2827
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Students for whom most of their closest friends were smokers
Number of subjects: 2827
Study 30813857 — intervention group
Group type: EXPERIMENTAL
Intervention: Students for whom a few of their closest friends were smokers
Number of subjects: 2827
Study 29172608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate approach using standardized outcomes
Number of subjects: 0
Study 27714758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block with 2 mg.kg-1 levobupivacaine
Number of subjects: 108
Study 27714758 — intervention group
Group type: COMPARATOR
Intervention: Spinal morphine 100 μg plus a sham ultrasound-guided fascia iliaca block using saline
Number of subjects: 108
Study 23716037 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 10 mg
Number of subjects: 286
Study 23716037 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 25 mg
Number of subjects: 286
Study 23716037 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg
Number of subjects: 286
Study 23716037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 23019990 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral barium sulphate suspension (900 ml, 0.1% w/v)
Number of subjects: 156
Study 23019990 — intervention group
Group type: COMPARATOR
Intervention: Positive barium sulphate suspension (900 ml, 2.1% w/v)
Number of subjects: 156
Study 23019990 — intervention group
Group type: COMPARATOR
Intervention: Water (900 ml)
Number of subjects: 156
Study 20238255 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion at a dose of 0.29 IU.min(‐1)
Number of subjects: 40
Study 20238255 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dose of oxytocin infusion was 0.4 IU.min(‐1)
Number of subjects: 40
Study 17512704 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 689
Study 17512704 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 250 mg twice daily
Number of subjects: 689
Study 16015542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (AMF)
Number of subjects: 62
Study 16015542 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 12368510 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-cell stent (NIR)
Number of subjects: 54
Study 10404959 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 16
Study 10404959 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 16
Study 10404959 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 16
Study 10404959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7752586 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐1 (rhIGF‐1) 50 micrograms/kg
Number of subjects: 18
Study 7752586 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐1 (rhIGF‐1) 100 micrograms/kg
Number of subjects: 18
Study 7752586 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐1 (rhIGF‐1)
Number of subjects: 18
Study 2281247 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (25 mg/kg h.s. and 3 h later)
Number of subjects: 20
Study 7330791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 10
Study 7330791 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 7330791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aminophylline and salbutamol
Number of subjects: 10
Study 7330791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31136202 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy (HT)
Number of subjects: 18
Study 31136202 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 28937248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent TBS (iTBS)
Number of subjects: 19
Study 28937248 — intervention group
Group type: COMPARATOR
Intervention: Sham (intermediate TBS; imTBS)
Number of subjects: 19
Study 25001020 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUD)
Number of subjects: 138
Study 25001020 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone (oral)
Number of subjects: 138
Study 23328689 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty and stenting for ICAD
Number of subjects: 21
Study 21122856 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol enriched margarine (2.5g/day)
Number of subjects: 30
Study 21122856 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol enriched margarine (2.5g/day)
Number of subjects: 30
Study 21122856 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched margarine (2.5g/day)
Number of subjects: 30
Study 16458215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% in cardioplegic mixture
Number of subjects: 21
Study 16458215 — intervention group
Group type: COMPARATOR
Intervention: Control (no sevoflurane in cardioplegia)
Number of subjects: 21
Study 14969664 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol (EE) + 100 microg levonorgestrel (LNG) (20/100)
Number of subjects: 48
Study 14969664 — intervention group
Group type: COMPARATOR
Intervention: 30 microg ethinylestradiol (EE) + 150 microg levonorgestrel (LNG) (30/150)
Number of subjects: 48
Study 11270908 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam-XR (4 mg/day mean dose)
Number of subjects: 38
Study 11270908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9815742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclic retinoid (600 mg daily)
Number of subjects: 42
Study 9815742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9815742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclic retinoid
Number of subjects: 42
Study 8179133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented components
Number of subjects: 20
Study 8179133 — intervention group
Group type: COMPARATOR
Intervention: Uncemented components
Number of subjects: 20
Study 3345456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (Sirdalud)
Number of subjects: 66
Study 3345456 — intervention group
Group type: COMPARATOR
Intervention: Baclofen (Lioresal)
Number of subjects: 66
Study 31201109 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam bleomycin
Number of subjects: 30
Study 31201109 — intervention group
Group type: COMPARATOR
Intervention: Liquid bleomycin
Number of subjects: 30
Study 29764409 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps-plus-hip-abductor-strengthening
Number of subjects: 80
Study 29764409 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps-strengthening
Number of subjects: 80
Study 26657031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Len meditation
Number of subjects: 103
Study 26657031 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 26657031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Tong Len and Control)
Number of subjects: 103
Study 24797698 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope®
Number of subjects: 23
Study 24797698 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 23
Study 24797698 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 23
Study 24797698 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 23
Study 23419999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention DFACs
Number of subjects: 602
Study 19897064 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure physical activity participation (TAS mean=105, range=0‐840)
Number of subjects: 234
Study 18062830 — intervention group
Group type: EXPERIMENTAL
Intervention: High folate intake (highest tertile)
Number of subjects: 1864
Study 18062830 — intervention group
Group type: COMPARATOR
Intervention: Low folate intake (lowest tertile)
Number of subjects: 1864
Study 18062830 — intervention group
Group type: COMPARATOR
Intervention: Folate intake (general)
Number of subjects: 1864
Study 16424795 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 20 mg/d for 15 days
Number of subjects: 14
Study 16424795 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 14
Study 14976862 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based intervention (early echocardiography, aggressive diuretic therapy, comprehensive education, prescribed diet, intensive pharmacological therapy)
Number of subjects: 100
Study 14976862 — intervention group
Group type: COMPARATOR
Intervention: Control (normal discharge after longer stay)
Number of subjects: 100
Study 10702763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg per os, once a day
Number of subjects: 109
Study 10702763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 9329979 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone (hrGH, 6 mg/d for 2 wk)
Number of subjects: 0
Study 9329979 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 9329979 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone (hrGH)
Number of subjects: 0
Study 8492725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 g arginine hydrochloride in 200 mL saline
Number of subjects: 5
Study 8492725 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of hydrocortisone combined with 200 mL saline
Number of subjects: 5
Study 2874824 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 4
Study 2874824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 4
Study 2874824 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 4
Study 2874824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4
Study 2874824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31441379 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 160
Study 31441379 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 100 mg
Number of subjects: 160
Study 29744791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine at 5 mg/day from day 1 to 5 during the second course of chemotherapy
Number of subjects: 50
Study 29744791 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antiemetic therapy without olanzapine)
Number of subjects: 50
Study 29744791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine group
Number of subjects: 50
Study 29744791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27866129 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 280
Study 27866129 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 280
Study 25051098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test
Number of subjects: 900
Study 25051098 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2) test
Number of subjects: 900
Study 25051098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test with cut-off at 5.0
Number of subjects: 900
Study 25051098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test with cut-off at 1.93
Number of subjects: 900
Study 22797645 — intervention group
Group type: EXPERIMENTAL
Intervention: 420-mg silymarin
Number of subjects: 154
Study 22797645 — intervention group
Group type: EXPERIMENTAL
Intervention: 700-mg silymarin
Number of subjects: 154
Study 22797645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, and prednisone (VMP)
Number of subjects: 682
Study 20368561 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP)
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent thalidomide-based therapies
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent lenalidomide-based therapies
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent bortezomib-based therapy
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent therapy (VMP)
Number of subjects: 682
Study 20368561 — intervention group
Group type: COMPARATOR
Intervention: Subsequent therapy (MP)
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during cycles 1 to 4 (VMP)
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during cycles 5 to 9 (VMP)
Number of subjects: 682
Study 20368561 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy events (VMP)
Number of subjects: 682
Study 18216062 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred education (PCE)
Number of subjects: 146
Study 18216062 — intervention group
Group type: COMPARATOR
Intervention: Standard patient education (SPE)
Number of subjects: 146
Study 15980684 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC/ZDV+EFV
Number of subjects: 448
Study 15980684 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC/ZDV
Number of subjects: 448
Study 12455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patches applied every 24 hours (group 1)
Number of subjects: 20
Study 12455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patches applied every 12 hours (group 2)
Number of subjects: 20
Study 12455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patches (both groups)
Number of subjects: 20
Study 10476515 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE (extracapsular cataract extraction)
Number of subjects: 34
Study 10476515 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 34
Study 8960841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 [7-36 amide] (1.5 nmol/kg body weight)
Number of subjects: 24
Study 8960841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 [7-36 amide] (single injection 30 min before a meal)
Number of subjects: 24
Study 8960841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 [7-36 amide]
Number of subjects: 24
Study 1672843 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) after a 7-day therapy
Number of subjects: 20
Study 1672843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1672843 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) after both short- and long-term therapy
Number of subjects: 20
Study 7050302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 59
Study 7050302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 30387144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of high-intensity exercise training (n=34)
Number of subjects: 61
Study 30387144 — intervention group
Group type: COMPARATOR
Intervention: Control/yoga group (n=27)
Number of subjects: 61
Study 29395880 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids CafÃ© Program nutrition education intervention
Number of subjects: 120
Study 29395880 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 120
Study 27591761 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-selected music characteristics
Number of subjects: 27
Study 27591761 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention interviews
Number of subjects: 27
Study 24393781 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic locomotor training plus overground therapy (LKOGT) for 60 minutes, 5 days per week for 8 weeks.
Number of subjects: 88
Study 24393781 — intervention group
Group type: COMPARATOR
Intervention: Conventional overground training (OGT) for 60 minutes, 5 days per week for 8 weeks.
Number of subjects: 88
Study 22990398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-cellulose dressing (BWD)
Number of subjects: 48
Study 22990398 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent dressing (control)
Number of subjects: 48
Study 20071293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with gemcitabine and cisplatin
Number of subjects: 52
Study 20071293 — intervention group
Group type: COMPARATOR
Intervention: Intravesical instillation with epirubicin
Number of subjects: 52
Study 17986290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation (PEX) syndrome
Number of subjects: 339
Study 17986290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) in PEX eyes
Number of subjects: 339
Study 17986290 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma (OAG) prevalence
Number of subjects: 339
Study 15589440 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive spa therapy program for 21 days
Number of subjects: 50
Study 12511211 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed condom use
Number of subjects: 779
Study 12511211 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom slippage and/or breakage
Number of subjects: 779
Study 12511211 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of delayed condom use
Number of subjects: 779
Study 12511211 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of condom slippage and/or breakage
Number of subjects: 779
Study 12511211 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of condom use
Number of subjects: 779
Study 9798817 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention providers trained in a brief alcohol-counseling intervention with office support system.
Number of subjects: 29
Study 9798817 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention providers trained in a brief alcohol-counseling intervention.
Number of subjects: 29
Study 9798817 — intervention group
Group type: COMPARATOR
Intervention: Usual care providers.
Number of subjects: 29
Study 7649598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (AMP)
Number of subjects: 0
Study 7649598 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (SV)
Number of subjects: 0
Study 2549535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 12
Study 2549535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 263816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0
Study 263816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 0
Study 263816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31480097 — intervention group
Group type: EXPERIMENTAL
Intervention: Echidna pin
Number of subjects: 28
Study 31480097 — intervention group
Group type: COMPARATOR
Intervention: Knowles pin
Number of subjects: 28
Study 27780709 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative coffee consumption (3 times daily)
Number of subjects: 114
Study 27780709 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative care without coffee consumption (Control)
Number of subjects: 114
Study 27780709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 25572773 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein group (HP)
Number of subjects: 0
Study 25572773 — intervention group
Group type: COMPARATOR
Intervention: Lower protein group (LP)
Number of subjects: 0
Study 25572773 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (observational group)
Number of subjects: 0
Study 22488012 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 40
Study 22488012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 22488012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PRP and Control)
Number of subjects: 40
Study 21392609 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 3414
Study 21392609 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 3414
Study 19673939 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin
Number of subjects: 166